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Abstract
Allergen immunotherapy presents an opportunity to define mechanisms of induction of clinical tolerance in humans.
Significant progress has been made in our understanding of changes in T cell responses during immunotherapy, but
existing work has largely been based on functional T cell assays. HLA-peptide-tetrameric complexes allow the tracking of
antigen-specific T-cell populations based on the presence of specific T-cell receptors and when combined with functional
assays allow a closer assessment of the potential roles of T-cell anergy and clonotype evolution. We sought to develop tools
to facilitate tracking of antigen-specific T-cell populations during wasp-venom immunotherapy in people with wasp-venom
allergy. We first defined dominant immunogenic regions within Ves v 5, a constituent of wasp venom that is known to
represent a target antigen for T-cells. We next identified HLA-DRB1*1501 restricted epitopes and used HLA class II tetrameric
complexes alongside cytokine responses to Ves v 5 to track T-cell responses during immunotherapy. In contrast to previous
reports, we show that there was a significant initial induction of IL-4 producing antigen-specific T-cells within the first 3–5
weeks of immunotherapy which was followed by reduction of circulating effector antigen-specific T-cells despite escalation
of wasp-venom dosage. However, there was sustained induction of IL-10-producing and FOXP3 positive antigen-specific T
cells. We observed that these IL-10 producing cells could share a common precursor with IL-4-producing T cells specific for
the same epitope. Clinical tolerance induction in humans is associated with dynamic changes in frequencies of antigen-
specific T-cells, with a marked loss of IL-4-producing T-cells and the acquisition of IL-10-producing and FOXP3-positive
antigen-specific CD4+ T-cells that can derive from a common shared precursor to pre-treatment effector T-cells. The
development of new approaches to track antigen specific T-cell responses during immunotherapy can provide novel
insights into mechanisms of tolerance induction in humans and identify new potential treatment targets.
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Introduction
The ability to induce clinical tolerance in humans carries
enormous therapeutic potential. Whilst allergen desensitization is a
long established approach for allergic disease [1–4], the critical
underlying mechanisms are still debated. Early clinical tolerance
occurs in the face of persisting antigen-specific IgE and can be
mediated, at least in part, by the passive transfer of IgG derived
from previously exposed, but tolerant individuals [4]. Thus specific
IgG blocking antibodies have been implicated in the generation of
early clinical non-responsiveness [5–6] and may be induced
through local and systemic IL-10 derived from regulatory T cells
and other cells [5]. Indeed CD4+CD25+ cells have been
documented to accumulate systemically and at sites of allergen
immunotherapy in some studies of successful desensitization
[7–10]. Allergen desensitization may also be accompanied by a
shift from a largely Th2 dominated cytokine production pattern to
one in which Th1 cytokines predominate [11–44]. Whole antigen
immunotherapy carries a risk of anaphylaxis, and therefore
peptide based approaches have attracted significant interest.
However peptide immunotherapy carries risk of late phase disease
exacerbation, possibly due to induction of antigen-specific effector
T cell responses [45–50]. Such exacerbations may be peptide dose
dependent and clearly it will be important to define the optimal
parameters for success [51].
Studies of T cell responses during immunotherapy have largely
used approaches based on analysis of overall populations of cells or
on cytokine-producing sub-populations of cells derived after
antigenic stimulation. In contrast, HLA-peptide tetrameric
complexes facilitate the identification and characterisation of
antigen-specific T cells without the need for the cells to express
particular functional activities. Such an approach therefore allows
the analysis of populations of antigen-specific T cells at the epitope
level and potentially permits a longitudinal assessment of the
relative contributions of deletion, anergy, cytokine switching and
regulatory T cell induction to the changing T cell profile during
immunotherapy.
Wasp venom immunotherapy is licensed in the United
Kingdom for the management of individuals with a history of
severe systemic reactions to wasp stings. We have previously
shown that the dominant antigens recognized by T cells are
antigen 5 (Ves v 5), hyaluronidase (Ves v 2) and phospholipase A1
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components. In addition, a number of antigenic regions of antigen
5 have been described with differential recognition patterns
between allergics and non-allergics [53]. However in order to
apply the HLA-peptide tetrameric complex technology to the
study of antigen-specific T cell responses, it is essential to have
detailed epitope mapping data, which are not currently available
for wasp venom specific proteins.
We sought to develop tools to enhance our ability to track
antigen-specific T cells during immunotherapy. We were limited
to using HLA class II restrictions for which HLA peptide
tetrameric complexes could be generated. Based on previous
studies, we focused on HLA-DRB1*1501 as this allele is relatively
common within the UK and HLA-DRB1*1501-restricted re-
sponses specific to other allergens can be detectable ex vivo and
after short term culture [54–56].
Results
Patient characteristics
We recruited 23 wasp allergic patients that had systemic allergic
reactions. Table 1 details the severity of reaction according to
Brown’s grading [57], the proportion of males and females, the
mean wasp venom specific IgE responses and the mean age. The
HLA DR types are given in table 2.
Antigen 5-specific functional T cell responses
Having previously documented that high frequencies of wasp
venom-specific T cells circulate in allergic individuals and that
antigen 5 (Ves v 5) is a dominant target antigen [52], we
proceeded to characterize constituent epitopes. Using peripheral
blood mononuclear cells (PBMC) derived from 23 wasp allergic
individuals, we first investigated the presence of circulating
cytokine-producing T cells that were reactive to overlapping
peptide pools derived from Ves v 5 (antigen 5, 4 pools of 20 amino
acid peptides, each overlapping by 10 amino acids). The ex vivo
frequency of IL-4 producing cells was low, with mean response of
12.4 spot forming units (sfu)/million PBMC for Ves v 5 and
interestingly the majority were directed against peptide pool 4
(Figure S1). We therefore examined the proliferative capacity of
the Ves v 5-specific T cells using cultured ELISpot. Following 10
days in culture, we observed significant expansion of Ves v 5-
specific responses with a mean of 1032 sfu/million cells for IL-4
and 781.3 sfu/million cells for IFNc (Figure S2). The IL-4
responses were significantly higher in individuals with allergic
disease than in exposed non-allergic individuals (1032 sfu/million
cells and 353.1 sfu/million cells respectively, P,0.05), but the
IFNc responses were not significantly different (781.3 sfu/million
cells and 481.9 sfu/million cells respectively, p=0.18).
We also used whole recombinant Ves v 5 to confirm that the
antigen is processed and presented, leading to proliferation in
antigen-specific T cells. PBMC derived from allergic and non-
allergic individuals were incubated with recombinant Ves v 5
(1 mg/ml), and then tested 10 days later for cytokine productivity
in response to recombinant Ves v 5. Figure 1 shows examples of
such analyses and that IL-4 producing T cells specific to
recombinant Ves v 5 were significantly more common in allergic
individuals than healthy controls. Interestingly, there was no
significant difference in the proportion of Ves v 5-specific IL-10
and IFN-c producing cells between the groups. Furthermore,
although the cytokine production was largely contained within the
CD4+ subset of cells, it was clear that allergen-specific CD8+ T
cells were also detected after day 10 cultures (data not shown).
Overall these results showed that both wasp allergic and
exposed non-allergic individuals have circulating Ves v 5-specific
CD4+ T cells that are able to proliferate and produce effector
cytokines, but in allergic individuals the frequencies of such cells
are higher and the responses biased towards Th2 cytokine
production.
Identification of DRB1*1501-restricted epitopes within
Ves v 5
Having characterised the overall Ves v 5-specific responses to
recombinant protein and overlapping pools, we were able to
proceed to map individual T cell epitopes. We were able to map
DRB1*1501 restricted epitopes by first expanding allergen specific
T-cells in vitro by incubating PBMC from DRB1*1501 allergic
individuals with recombinant Ves v 5. These T-cell lines were then
screened for cytokine production at day 10 of culture using
DRB1*1501-transfected murine L cells pulsed with the Ves v 5-
derived peptide pools. We noted that pool 4 frequently induced
Table 1. Clinical characteristics of the 23 patients enrolled in the study.
Sex Male; number of patients (percentage) 16 (66%)
Female; number of patients (percentage) 8 (34%)
Age (mean, standard deviation) 54 (11.04) years
Severity of anaphylaxis Brown’s grade 2; number of patients (percentage) 15 (63%)
Brown’s grade 3; number of patients (percentage) 9 (37%)
Wasp venom specific IgE, mean (standard deviation) 19 KU/L (10)
doi:10.1371/journal.pone.0011028.t001
Table 2. HLA-DR types of 23 patients enrolled in the study.
HLA type number of patients (percentage)
HLA DRB1*01 5 (21)
HLA DRB1*03 6 (25)
HLA DRB1*04 6 (25)
HLA DRB1*07 5 (21)
HLA DRB1*08 1 (4)
HLA DRB1*11 6 (25)
HLA DRB1*12 3 (13)
HLA DRB1*13 2 (8)
HLA DRB1*14 1 (4)
HLA DRB1*15 6 (25)
HLA DRB1*16 1 (4)
doi:10.1371/journal.pone.0011028.t002
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constituent peptides (Figure 2A and D). In some individuals,
peptide 19 induced the DRB1*1501 restricted response (example
in Figure 2B). The epitope was fine mapped using serial
truncations from peptide termini and showed the optimal epitope
to be HKHYLVCNYGPSGN (Figure 2C). In other individuals,
peptide 16 induced the dominant DRB1*1501 restricted responses
(Figure 2E). The minimal epitope was also fine mapped using
serial truncations and found to be LKTGHYTQM (Figure 2F).
However the optimal response was noted to comprise the slightly
longer peptide NDFLKTGHYTQMVWA (data not shown).
Furthermore, the NDFLKTGHYTQMVWA 15mer was predict-
ed by an online class II prediction software syfpeithi (http://www.
syfpeithi.de/).
Having mapped the novel epitopes within antigen 5, we were in
a position to use Ves v 5/DRB1*1501 peptide tetrameric
complexes. As well as staining ex vivo, we were also able to use
tetramer-guided cell sorting to generate T cell clones from allergic
individuals. Figure 3a-c shows examples of tetrameric complex
staining of day 14 cultures and of a clonal population of cells; 3a
shows staining of the Ves v 5 line to a control varicella zoster
virus/DRB1*1501 tetramer. Figure 3d shows overall ex vivo
responses in patients and controls.
Longitudinal functional responses
Previous studies have suggested that there is a progressive loss of
IL-4 producing allergen-specific T cells during immunotherapy
[15,20–21,38,58–60]. However, these studies detect cytokine
responses after in-vitro expansion of cells and few studies have
examined frequent responses at weekly intervals during immuno-
therapy. By determining ex vivo frequencies of wasp venom specific
cytokine secreting T-cells by ELISpot and in contrast to previous
studies, we observed an initial significant (P,0.05) induction of IL-
4 producing T cells specific for whole wasp venom that reached a
peak between weeks 3–5 of immunotherapy before falling through
to week 12 (Figure 4). Furthermore we observed a similar
induction of IL-10 producing cells during weeks 3-5 but after a
subsequent fall, this was followed by a sustained increase to week
12 (Figure 4). Figure 4b shows the IL-10 to IL-4 ratio at weeks 0
and 12 of immunotherapy. These longitudinal changes in
frequency of cytokine secreting cells are also antigen-specific, as
IFN-c responses to a ‘‘FEC’’ control peptide pool (32 CD8+ T-cell
epitopes from EBV, CMV, and influenza [61]) did not change
over time (Figure S3). In addition to these changes in the
frequency of antigen-specific cytokine secreting T-cells we also
observed an increase in venom specific IgG4 during immuno-
therapy (Figure S4).
These data showed that IL-4 producing wasp venom-specific T
cells are initially induced during immunotherapy, but after weeks
3-5 the functional IL-4 responses are progressively lost through to
week 12. However, it is not clear whether this represents loss of
circulating specific cells and/or change in cell function. In order to
address this question, we used the two Ves v 5/DRB1*1501
tetrameric complexes to track epitope specific T cells over time in
Figure 1. Ves v 5 specific cytokine responses in wasp allergy. A. T-cells were cultured for 10 days in the presence of recombinant Ves v 5 and
IL-4 and IL-10 production was determined after re-stimulation with recombinant Ves v 5 (lower) and PBS - negative control (top). B. Cytokine
responses of Ves v 5 T-cell lines after re-stimulation with antigen. IL-4 responses to Ves v 5 is significantly higher in individuals with a history of wasp
venom anaphylaxis (N=6) than non-allergic controls (N=6) (P,0.05), whereas the frequency of IL-10 and IFN-c responses does not differ between
the 2 groups; student’s t-test.
doi:10.1371/journal.pone.0011028.g001
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DRB1*1501. Frozen PBMC taken from an individual at different
stages of immunotherapy were thawed and stained with tetramer
at the same time, thus limiting any time related degradation of
tetramer or other variation related to analyses taken at different
times. We would have liked to have investigated the longitudinal
frequency of tetramer binding T-cells in HLA-DRB1*1501 wasp
allergic individuals not receiving immunotherapy but as our cohort
all undergo immunotherapy we instead demonstrated that the
frequency of tetramer binding CD4 T-cells did not significantly
change with time in healthy individuals not receiving immuno-
therapy (Figure S5). HLA peptide tetrameric complex binding to
T cells is not dependent on particular functional activity and will
therefore detect all epitope-specific T cells regardless of functional
subset. Figure 5A gives an example of Ves v 5 HLA-DRB1*1501
tetramer binding of CD4 T-cells in a wasp allergic individual
during immunotherapy alongside the frequency of CD4+ T-cells
binding to a control hCLIP-HLA DRB1*1501 tetramer in the
same individual. In figures 5B and C ex vivo Ves v 5 tetramer and
control hCLIP tetramer binding was followed in 6 individuals
longitudinally and confirms a similar initial induction to weeks 4,
followed by a loss of cells to a level not significantly different to the
start of immunotherapy. The frequency of CD4+ T-cells binding
to a control hCLIP-HLA DRB1*1501 tetramer in the same
individuals did not change significantly (Figure 5B). Whilst this
implicates a relative loss of specific T cells during later
immunotherapy, it does not indicate phenotypic or functional
characteristics of the remaining cells. Figure 6 (A and B) shows
identification of antigen-specific tetramer-binding T-regs by gating
on FOXP3-positive and CD25hi as shown in the tetramer
negative population. Figure 6D shows that the proportion of Ves
v 5-specific T cells that were FOXP3-positive also increased over
time compared to the tetramer-negative population and this
proportion was maintained to week 8 of immunotherapy.
Furthermore, we observed that the proportion of tetramer-positive
cells that expressed CD45RO was significantly lower at week 4
and week 8 compared to pre-treatment levels (data not shown).
FOXP3 is expressed at constitutively high levels on natural T
regulatory cells but can be induced on both effector T cells and on
acquired T regulatory cells[62–63]. However little is known of the
relationship between the latter two populations and whether they
originate from common precursor cells. The frequency of Ves v 5-
specific T cells was too low ex vivo for use in suppression assays, but
we were able to investigate whether the fall in antigen-specific T
cells was IL-10 dependent. We observed that the addition of anti-
IL-10 restored the proliferation and IL-4 production of Ves v 5-
specific T cell during the course of immunotherapy (Figure 7).
Indeed, we observed significant (P,0.005) further enhancement
when anti-CD25 was used to deplete PBMC of CD25hi T-regs in
addition to the anti-IL-10 (Figure S6). Taken together with the
FOXP3 findings, these data argue in favour of induction of
acquired antigen-specific FOXP3-positive regulatory T cells and
IL-10 secreting regulatory T cells during wasp venom immuno-
therapy which influence the frequency and function of venom-
specific IL-4 producing effector T cells. Indeed, allergen specific
IL-10 secreting cells have been demonstrated to occur in healthy
controls and in bee-keepers.
However the data do not address the origin of the acquired
regulatory T cells and whether they arise from the IL-4 producing
effector T cells or whether they represent a distinct lineage that is
induced during immunotherapy. In order to address this question,
we used cytokine capture assays to isolate Ves v 5-specific T cells
on the basis of IL-4, IFNc and IL-10 production over time. The T
cell receptor genes of the clones were then sequenced in order to
determine the nature of lineage consistencies. We used a whole
Ves v 5 stimulation approach in order to avoid bias towards one
Figure 2. Identification of DRB1*1501-restricted epitopes within Ves v 5. T-cell lines from two wasp allergic patients to rVes v 5 were re-
stimulated with Ves v 5 peptide pools (a and d) and IL-4 ELISpot responses were detected to pool 4. DRB1*1501 transfected L-cells were then
separately pulsed with constituent peptides from peptide pool 4 and used to stimulate rVes V 5 lines; peptides 19 and 16 were thus identified as
containing HLA-DRB1*1501 restricted epitopes (b and e, respectively). T-cell lines were generated against rVes v 5 from 5 venom allergic patients and
IL-4 responses were determined for different p19 (c) and p16 (f) derived sequences to reveal the minimal epitopes. SFU=spot forming units.
doi:10.1371/journal.pone.0011028.g002
T-Cells and Clinical Tolerance
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11028particular epitope. Many clones were identified (Figure 8), but
surprisingly we observed one clone that emerged from one
individual at 2 separate time points derived from different
populations of cytokine production. At week 1, the clone had
been isolated on the basis of IL-4 production in response to the
entire overlapping Ves v 5 peptide pools. However by week 4, the
clone was not isolated from the IL-4 producing population, but
was instead isolated from both the IL-10 and IFNc producing
subsets. Furthermore, we went on to observe that the clone
recognised our peptide NDFLKTGHYTQMVWA and stained
with the relevant tetramer. These data show that a single TCR
precursor can give rise to IL-4, IFNc or IL-10-producing cells at
different stages of immunotherapy that accompanies acquisition of
clinical tolerance. Taken together with the tetramer and FOXP3
data documented above, these findings would be compatible with
antigen-specific acquired regulatory T cells being derived from a
common precursor to effector T cells in humans.
Discussion
Wasp venom immunotherapy presents an excellent opportunity
to understand the acquisition of clinical tolerance in humans. The
administration of weekly subcutaneous injections of wasp venom
to humans is associated with changes in systemic immune
responses with consequent well-documented clinical efficacy.
Investigation of the underlying mechanisms carries significant
implications for understanding peripheral tolerance as well
as leading to potential future therapeutic developments in the
Figure 3. Detection of Ves v 5 specific T-cells with MHC Class II Ves v 5 tetrameric complexes. Examples of DRB1*1501 tetramer staining
of a day 14 cultured population using a control DRB1*1501 Varicella zoster virus peptide tetramer (a) and a wasp venom Ves v 5 DRB1*1501 tetramer
(b). The Ves v 5 DRB1*1501 tetramer was also used to stain a clonal population (c). d. Ex vivo frequency of tetramer-binding cells from individuals with
a history of anaphylaxis to wasp venom (N=6) was significantly higher than from DRB1*1501-positive non-allergic controls (with a history of wasp
stings, N=4) and DRB1*1501-negative individuals (N=4); p,0.05, student’s t-test.
doi:10.1371/journal.pone.0011028.g003
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transplantation.
A key step in the investigation of T-cell responses is to identify
T-cell antigens, map epitopes and determine HLA-restriction.
Having previously identified the major T-cell antigenic sources in
wasp venom as Ves v 1, Ves v 2 and Ves v 5 [64], we have now
identified 2 HLA DRB1*1501 restricted epitopes within Ves v 5
using T-cell lines from wasp allergic individuals. Bohle et al also
identified T-cell epitopes in 13 wasp allergic patients and 13
healthy controls by using overlapping synthetic peptides, although
they did not did not determine HLA restriction [53]. Interestingly,
T-cell clones from three of their HLA-DRB1*1501 expressing
allergic patients recognised peptides containing the 2 HLA-
DRB1*1501 T-cell epitopes that we identified.
The identification and fine mapping of Ves v 5 epitopes also
allowed for the development of HLA-DRB1*1501-Ves v 5 peptide
tetrameric complexes, and through their subsequent use we were
able to identify antigen specific T-cells in both allergic individuals
and healthy controls. Although the frequency of tetramer positive
cells was very low ex vivo (0.01–0.09% of CD4+ T cells), it is
comparable to frequencies of tetramer positive cells detected in cat
allergy and after varicella zoster exposure [65-66]. The wasp
allergic patients had higher frequencies of allergen specific T-cells
as defined by tetramer binding and functional cytokine responses,
which has been similarly observed in cat and pollen allergy
[66–67]. We hope that the identification of wasp venom specific
epitopes and the consequent availability of wasp venom-specific
HLA tetrameric complexes will aid such future monitoring in the
further development of wasp venom immunotherapy, with lessons
for other diseases.
By mapping constituent epitopes within a dominant antigen of
wasp venom, we have been able to take a new approach to the
characterization of T cell correlates of successful immunotherapy
in wasp venom allergic individuals. In contrast to previous studies,
we have shown that during the first 3–5 weeks of immunotherapy
there is an induction of effector T cells, which is then later followed
by a relative loss of such cells in the group of 13 wasp-venom
patients from whom we longitudinally tracked cytokine responses.
We have also observed that immunotherapy is associated with the
acquisition of IL-10-producing antigen-specific cells that can
derive from a common precursor to effector T cells. Lastly the fall
in antigen-specific T cells during late immunotherapy is partially
IL-10 dependent.
The early induction of IL-4-producing antigen-specific T cells in
the first few weeks of immunotherapy would fit with observations
of late asthmatic reactions in individuals receiving peptide
immunotherapy for cat allergen reactive asthma [45–50]. It might
also contribute to reactions observed in other immunotherapeutic
uses of peptide [68–69]. It has previously been well argued that
such reactions may be dose dependent and indeed there are likely
to be therapeutic strategies that reduce the associated risk [51].
Clearly an understanding of such an early induction of effector T
cells will be crucial for the progression of peptide immunotherapy
approaches. It is perhaps unsurprising that administration of an
antigen leads to induction of immune responses, and indeed this is
the aim of current vaccination approaches. However, the causes of
the subsequent reduction in allergen specific reactivity despite
antigen dose escalation, is key to understanding mechanisms of
clinical tolerance.
We observed that the later fall in IL-4 producing wasp venom-
specific T cells was associated with a loss of tetramer-binding cells
in the 6 HLA-DRB1*1501 wasp allergic patients from whom we
had longitudinal samples. This argues that there is not simply a
change of function of antigen-specific T cells, but also a reduction
in the circulating frequency of reactive T cells. Although we
cannot exclude the redistribution of antigen-specific T-cells from
the periphery, it is also possible that activation induced cell death is
accounting for this loss. One limitation of the tetramer approach is
that for CD4+ T cells, it is necessary to gate out dying cells, which
means that investigation of mechanisms of cell death in the
tetramer-binding population is problematic. Sorting of tetramer-
binding cells also potentially introduces artefacts which have
limited our ability to address this question. Nevertheless it is clear
that there is a fall in wasp venom-specific T cells between weeks 4
and 8 of immunotherapy which associates with a reduction in
antigen-specific IL-4 production.
The fall in IL-4 production by wasp venom specific T cells
during late immunotherapy is accompanied by a rise in the
proportion of remaining allergen-specific T cells that produce IL-
10. Furthermore the proportion of the tetramer-binding cells that
express FOXP3 also increases, and the loss of IL-4 production is
Figure 4. Longitudinal ex-vivo cytokine responses to immuno-
therapy. A. Ex vivo longitudinal frequencies of cytokine producing
cells during immunotherapy in response to whole wasp venom in 13
wasp allergic patients. Circles IL-10, triangles IL-4, diamonds IFN-c. SFU
(spot forming units). There was a significant effect of the week of
immunotherapy on the frequency of IL-10 and IL-4 secreting T-cells
(one-way ANOVA p=0.0284 and p=0.0368, respectively) and there was
a significant rise in IL-4 and IL-10 responses at week 5 (p,0.05), which
for IL-10 was maintained at 12 weeks after starting immunotherapy
(p,0.05). Means and SD are displayed. B. Ratio of IL-10:IL-4 secretion
over time during immunotherapy in the same 13 wasp allergic patients;
p=0.03 student’s paired t-test.
doi:10.1371/journal.pone.0011028.g004
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provide evidence supporting the possibility that IL-10-producing
wasp venom-specific FOXP3-positive T cells are induced during
venom immunotherapy and influence antigen-specific production
of the effector Th2 cytokine IL-4. The lineage specificity of IL-10-
producing acquired T regulatory cells has been debated, but we
show that similar cells develop during immunotherapy and can
share a common precursor with pre-treatment effector Th2 cells in
humans. This suggests that repeated subcutaneous administration
of antigen in the absence of concurrent inflammation can lead to
either the switch of existing effector IL-4 producing T cells to IL-
10 production or to the preferential outgrowth of IL-10 producing
cells with a shared common precursor. Akdis et al have also
recently shown that in bee-keepers who are exposed to high doses
of bee venom, there is evidence of clonality accompanying the
switch to IL-10 secreting T-cells [70].
It is possible that the observed venom-specific IL-10 producing
cells and FOXP3-positive cells represent an epiphenomenon and
Figure 5. Longitudinal analysis of tetramer-binding cells during immunotherapy. A. The top line of dot-plots show the frequency of HLA-
DRB1*1501 Ves V 5 peptide-tetramer binding cells from a wasp allergic patient before (week 0) and during immunotherapy. Binding of CD4+ T-cells
to the control hCLIP-HLA-DRB1*1501 tetramer is shown in the lower line of dot-plots. Numbers in the top right corner of dot-plots is tetramer binding
cells as a percentage of CD4+ T-cells. B. Antigen specific T-cell frequencies were followed in 6 HLA-DRB1*1501-positive individuals using HLA-
DRB1*1501 Ves v 5 peptide-tetrameric complexes. Frequencies were expressed as a percentage of CD4+ T cells. There was a significant reduction
(p,0.05) in the frequency of tetramer positive T-cells from weeks 4 to 7 using Student’s paired t-test. C. Tetramer binding to the control hCLIP-HLA-
DRB1*1501 tetramer was also followed in 4 of the individuals during immunotherapy. There was no significant change in the frequency of hCLIP-
tetramer binding cells, p=0.53, one-way ANOVA.
doi:10.1371/journal.pone.0011028.g005
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data on regulatory T cells and their relevance to many diseases,
suggest that these are likely to prove to be important cells in the
success of immunotherapy [71–73]. That IL-10 may play a role in
allergen tolerance has been suggested by a previous study that
demonstrated increased frequencies of allergen specific IL-10
secreting T-cells in healthy controls compared to allergic
individuals by ELISpot [74]. It will be of interest to examine the
frequencies of such cells in the subgroup of individuals who lose
clinical tolerance after many years of immunotherapy. Further-
more, the data do not address how the IL-10-producing FOXP3-
positive cells might influence the IgE-dependent clinical reactivity,
but the known IL-10 induced class switching to IgG4 in humans
may be relevant. Indeed, among laboratory animal handlers and
children, reduced prevalence of laboratory animal and cat allergy,
respectively, is associated with high serum concentrations of
allergen specific IgG4 and high animal exposure [75–76].
Interestingly, we also observed a significant rise in wasp- venom-
specific IgG4 after 8 weeks of immunotherapy consistent with
previous reports [4–6]. Further longitudinal studies on the
durability of Ves v 5 - specific T cells may help determine the
optimal duration of immunotherapy, which is empirically
determined at 3 to 5 years at present.
In summary, we have developed tools to facilitate the tracking of
T cells during clinical tolerance induction in humans, and use
these to show that wasp venom immunotherapy associates with an
initial induction of IL-4-producing wasp venom-specific T cells,
which is followed after 3–5 weeks by a fall in the frequency of cells
Figure 6. Longitudinal change in FOXP3+ T-cells during immunotherapy. A. Example of dot-plot showing frequency of HLA-DRB1*1501 Ves
V 5 peptide-tetramer binding cells from wasp allergic patient 7 weeks after immunotherapy. FOXP3+ CD25hi T-regs population were visualized in the
tetramer negative population and were gated as shown in B. This T-reg gate was used to identify antigen-specific tetramer-binding T-regs as shown
in C. D. The percentage of FOXP3 expressing cells within the tetramer-binding subset (open boxes) and the total CD4+ population (filled boxes) were
determined during immunotherapy in 6 DRB1*1501 wasp allergic patients.
doi:10.1371/journal.pone.0011028.g006
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expression. Furthermore, the IL-10 producing cells can share a
common precursor with pre-treatment IL-4-producing T cells
suggesting that acquired regulatory T cells in humans can be
derived from similar populations to effector T cells. The data
contribute to our understanding of clinical tolerance acquisition in
humans with consequent potential therapeutic implications in the
setting of allergy and other disease. We hope that the development
of such tools will be of value to those investigating allergen-specific
immune responses and mechanisms of tolerance induction.
Materials and Methods
Ethics Statement
The study was approved by Oxfordshire Research Ethics
Committee (REC) B - reference C02.291. All participants gave
written informed consent.
Subjects
Twenty three individuals with a clinical history of wasp venom
systemic allergic reactions and positive wasp venom specific skin
tests and/or circulating IgE detected by RAST who were to begin
an 8-weeks modified rush protocol of Vespula sp. Venom (ALK-
Abello) immunotherapy were recruited through the venom clinic
at the Churchill Hospital. Wasp allergic subjects were bled before
(week 0) and after (weeks 1–12) immunotherapy. 14 healthy
volunteers with a history of previous wasp stings, but without a
history of wasp venom allergy were also used. Details of the dose of
wasp venom that was administered subcutaneously were at weekly
intervals as follows: 3 mg, 5 mg, 10 mg, 20 mg, 40 mg, 65 mg,
100 mg, 100 mg. Peripheral blood mononuclear cells (PBMCs)
were separated from heparinized peripheral blood by density
gradient using Lymphoprep (Nycomed, Roskilde, Denmark).
PBMCs were then washed in RPMI supplemented with penicillin,
streptomycin and l-glutamine (R0) and resuspended in RPMI with
penicillin, streptomycin, l-glutamine and 10% fetal calf serum
(FCS; R10).
HLA Typing. All patients and laboratory volunteers
were HLA typed. Genomic DNA Puregene DNA isolation kit
(Gentra Systems, USA) was used to isolate DNA from whole
blood. HLA-A, -B, -C, DRB1, DRB3, DRB4, DRB5 and DQB1
specificities were determined using sequence specific primers by
our in-house HLA typing service.
Antigens
Ex-vivo ELISpot assays used Vespula species wasp venom
(Vespa Labs, Spring Mills, PA, USA) at 5 mg/ml and also synthetic
peptide pools. 20 mer peptides overlapping by 10 amino acids
which spanned the whole length of the Ves v 5 protein were
synthesized in house in an automated synthesizer using 9-
fluorenylmethoxycarbonyl chemistry. The purity of the peptides
was determined to be greater than 90% by high-pressure liquid
chromatography analysis and mass spectrometry. Individual Ves v
5 peptides were pooled to create 4 peptide pools with each pool
containing 5 peptides (peptide concentration of 20 mM). Recom-
binant Ves v 5 was a kind gift from R Suck (Allergopharma,
Germany) and was used to expand T-cell lines in vitro at 1 mg/ml
and for stimulation of T-cell lines at 100 mg/ml.
ELISpot
ELISpot plates (Millipore Corp., Bedford, MA, USA) were
coated with either anti-human interferon (IFN)-c, IL-4 or IL-10
antibody overnight (Mabtech AB, Nacka, Sweden). The plates
were washed six times with RPMI-1640 and blocked for 1 h with
RPMI-1640 supplemented with 2 mM L-glutamine, 100 IU/ml
penicillin and 100 mg/ml plus 10% human serum (R10*). For ex-
vivo responses, 0.2610
6 PBMC were stimulated with Vespula
species venom (final concentration 5 mg/ml) in 96 well ELISpot
plates. For ELISpot reponses using T-cell lines, 40,000 cells were
added to each well to which Ves v 5 peptide pools or individual
peptides were added (final concentration 20 mM). Wells were set-
up in duplicate. Phytohaemagglutinin was included as a positive
control and R10* alone was included as a negative control. After
overnight incubation at 37uC and 5% CO2, plates were washed x6
in PBS-Tween 0.05% and incubated with 1 mg/ml of biotin-linked
anti-IFN-c, IL-10 or IL-4 monoclonal antibody (mAb) (Mabtech
AB) for 2 hours. After washing x 6 in PBS-Tween 0.05%, the
plates were incubated for a further 1 hour with streptavidin-
alkaline phosphatase (Mabtech AB). Spots were visualized using an
alkaline phosphatase conjugate substrate kit (Biorad, Hercules,
CA, USA) and enumerated using an automated ELISpot reader.
Results were expressed as spot-forming cells per total number of
PBMCs after subtracting the background (cells alone).
T-cell lines
Antigen 5 specific T-cells were expanded in vitro by incubating
4610
6 PBMCs with recombinant Ves v 5 (10 mg/ml) in 2 mls
R10* in 24 –well plates for 10 days (Corning, ). Interleukin-2 was
added on days 3 and 7 at a concentration of 100 units/ml. Anti
human IL-10 (Peprotech Inc, Rocky Hill, NJ, USA) was also
added to certain lines on day 0, 3 and 10 to maintain a
concentration of 4 mg/ml. All cell lines were maintained at 37uC,
in 5% CO2. T cell lines were washed twice in PBS 24 hours before
their use in ELISpot and cytokine secretion assays.
Cytokine secretion assay
5610
6 recombinant Ves v 5 T-cell lines were stimulated with
10 mg/ml recombinant Ves v 5 in 1 ml of R10* in 24 well plates
for 6 hours at 37C in humidified 5%CO2. Cells were then
harvested and labelled with anti–IFNc/CD45, anti–IL-4/CD45,
and anti–IL-10/CD45 Ab–Ab conjugates according to the
manufacturer’s protocol (Miltenyi Biotec, Germany) for 5 min at
a concentration of 10
7 cells/ml in ice-cold phosphate buffered
saline pH 7.2, containing 0.5% bovine serum albumin (BSA) and
2 mM EDTA (PBS-EDTA). The cells were diluted with 37uC
R10* medium to a final concentration of 10
6 cells/ml and were
slowly rotated at 37uC for 45 minutes. The cells were then washed
Figure 7. IL-10 is inhibiting IL-4 responses in Ves v 5 specific
lines after immunotherapy. Production of IL-4 by day 14 cultured T
cells in response to recombinant Ves v 5 at different stages of
immunotherapy in the absence (open boxes) or presence (filled boxes)
of anti-IL-10. Addition of anti-IL-10 at week 7 restored the frequency of
rVes V 5 specific IL-4 T-cells (p=0.008, Student’s paired t-test).
doi:10.1371/journal.pone.0011028.g007
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anti–IFN-c (Miltenyi Biotec) APC-conjugated anti–IL-10 (Milte-
nyi Biotec), PE-conjugated anti–IL-4 (Miltenyi Biotec), Pacific
Blue conjugated anti-CD4 (BioLegend, CA, USA) and vital dye
Via-probe (BD PharMingen) for 10 min at 4uC. After washing,
cells were re-suspended in PBS 0.5% formaldehyde and acquired
on a CyAn
TM (DakoCytomation, Glostrup, Denmark) flow
cytometer. For cell sorting cells were re-suspended in PBS and
sorted on a MoFlo
TM (Beckman Coulter, Fullerton, CA,USA).
Tetramer staining
DRB1*1501 iTAg MHCII tetramer was purchased from
Beckman Coulter (Hialeah, FL, USA). DRB1*1501-PE tetramer
was complexed to Ves v 5 peptides NDFLKTGHYTQMVWA
and HKHYLVCNYGPSGNFKNEEL. hCLIP peptide HLA
DRB1*1501 negative control tetramer was provided by the
NIH Tetramer Core Facility (Emory Vaccine Center, Atlanta,
GA). Cell lines and PBMC were incubated with 2 mg/ml HLA
class II tetramer for 60 min at 37uC in R10* before staining with
cell surface marker antibodies at room temperature for 20
minutes, including CD4-pacific blue (Biolegend, San Diego, CA,
USA), CD14-PerCP, CD45RO APC, CD19-PerCP and vital dye
ViaProbe (all BD Pharmingen, Oxford, UK) were added for
20 min at room temperature. Stained cells were washed with
phosphate-buffered saline (PBS) and fixed in 0N5% PBS/
formaldehyde. For FOXP3 staining tetramer and cell surface
marker stained cells were then fixed permeabilised and stained
with anti-FOXP3 according to the manafacturer’s instructions
Figure 8. Identification and TCR sequencing of Ves v 5 specific T-cell clones during immunotherapy. A. IFN-c, IL-4 and IL-10 secreting
cells were sorted using a cytokine secretion assay from day 14 cultured Ves v 5-specific T cell populations. Clones were established by in vitro
expansion of single cytokine secreting cells. B. Cytokine secretion in response to antigen 5 stimulation was measured by ELISpot using IL-4 (black
boxes), IFN-c (red boxes) and IL-10 (blue boxes) derived clones, sorted before immunotherapy (week 0) and at weeks 4 and 8 of immunotherapy. Sfu
spot forming units. C. Clones 22.1, 8.4 and 10.4 (*) shared an identical TCR Vbeta sequence.
doi:10.1371/journal.pone.0011028.g008
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TM
(DakoCytomation) and analysed using FlowJo software. Dead
and CD14 and CD19 positive cells were excluded from the
analysis.
CD25 depletion
CD4+ CD25+ regulatory T-cells were depleted using anti-
CD25hi magnetic bead conjugated antibodies (Invitrogen Dynal
AS, Oslo, Norway) from PBMC from patients before and 12
weeks after immunotherapy. Conjugated beads were washed x3
in PBS-0.1% BSA using a magnet to remove the supernatant.
Beads (400 million beads/ml) were then mixed with PBMC (25
million/ml) and incubated at 4C for 30 min with gentle rolling.
Labelled cells were then removed using a magnet. Depletion of
CD4+ CD25+ T-cells was confirmed by flow cytometry (data not
shown).
T-cell cloning
IL-4. IL-10 and IFN-c secreting Ves v 5 specific CD4+ T-cells
were identified using the cytokine secretion assay and single cells
were sorted into individual well in round-bottomed 96-well plates
using a MoFlo cell sorter. Tetramer staining cells of PBMC
stimulated for 10-days with relevant peptide (2 mM) were also
similarly sorted by flow cytometry. 100 ml of irradiated feeder
cells – (1:1:1 of PBMC from 3 different individuals) at 1610
6 cells/
ml in R10* containing IL-2 (100 IU/ml) and PHA (1 mg/ml)
were added to each well. Clones were fed every 3–4 days with
R10* containing IL-2 (100 IU/ml) and were re-stimulated with
feeder cells every 2–3 weeks.
TCR Sequencing
RNA was extracted from CD4 clones using TRIzol LS
reagent (Invitrogen,Carlsbad, California, USA). Full length
cDNA was generated using a switching mechanism At 59 end
of RNA Transcript (SMART) (Clontech) using Superscript 3
reverse transcriptase (Invitrogen), oligo(dT) (Invitrogen), and
SMART II
TM A oligonucleotide (59-AAGCAGTGGTAT-
CAACGCAGAGTGrGrGr-39, where Gr is a ribonucleotide)
(Clontech, Mountain View, CA, USA). The cDNA was
subsequently used as a template for 59 rapid amplification of
C-terminal ends (59-RACE) using 59 universal primers (Clon-
tech), anti-sense TCR beta chain constant region primer,
TCRB 59-ATTCACCCACCAGCTCAGCTCCACG-39 and a
high-fidelity polymerase Advantage 2 (Clontech) and incorpo-
rating a touch-down polymerase chain reaction (PCR) protocol.
CDR3 regions were sequenced using the TCRB primer.
TCR V, D and J regions were identified using the
International Immunogenetics Information system (IMGT)
database [77–78].
Statistics
Appropriate statistical tests were used to determine if the null
hypothesis could be rejected at a probability of ,0.05. Paired t-
test, one-way ANOVA and Chi square test were used to establish
significance of differences between data-sets. All analysis
was performed using the statistical software package GraphPad
Prism 4.
Supporting Information
Figure S1 Ex vivo IL-4 ELISpot responses to Ves v 5 peptide
pools in 23 wasp allergic patients: in A, 92 responses representing
summed responses to 4 Ves v 5 pools were determined ex-vivo.
The horizontal dashed bar represents the cut-off for a positive
response (mean + 3x standard deviation of negative control wells).
Mean response is 12.4 SFU (spot forming units) per million
PBMC (solid line); whereas in B responses to each peptide pool
are shown, the horizontal bars representing the means for each
peptide pool and the cut off for a positive response is the
horizontal dashed line.
Found at: doi:10.1371/journal.pone.0011028.s001 (0.45 MB TIF)
Figure S2 IL-4 and IFN-c peptide responses after 10 day in vitro
expansion with recombinant Ves v 5 (1 mg/ml) followed by
overnight stimulation with Ves v 5 peptide pools at final
concentration of 10 mm. Responses within boxes were above the
cut-off (dashed line), which was determined as mean of negative
control plus 3x standard deviation: 249 for IL-4 and 204 for IFN-c.
The mean frequency of Ves v 5 peptide specific IL-4 secreting T-
cells was higher in wasp allergic patients than in controls: (mean
10326129.9 SFU per million cells N=23 for wasp allergics and
353.1 SFU per million cells 654.34 N=8 for controls (p=0.029).
There was no significant difference between the frequency of
IFN-c positive responses between venom allergics and controls,
781.36145.0 N=16 wasp allergics, 481.9695.13 N=8 controls
p=0.18.
Found at: doi:10.1371/journal.pone.0011028.s002 (4.52 MB TIF)
Figure S3 Longitudinal IFN- c response to control antigen in 4
wasp allergic individuals receiving immunotherapy. Ex-vivo
responses to FEC peptide pool was determined by ELISpot in
wasp allergic individuals during immunotherapy. There was no
significant difference between the mean responses. 1-way ANOVA
p=0.93.
Found at: doi:10.1371/journal.pone.0011028.s003 (0.81 MB TIF)
Figure S4 Longitudinal venom-specific IgG4 responses during
immunotherapy in 6 HLA-DRB1*1501 individuals before (week
0) and after immunotherapy (weeks 4 and 7). There was a
significant increase in serum IgG4 concentration after 4 and 7
weeks of immunotherapy (Student’s paired t-test).
Found at: doi:10.1371/journal.pone.0011028.s004 (0.21 MB TIF)
Figure S5 Frequency of tetramer specific T-cells was enumer-
ated by flow cytometry in 4 HLA DRB1*1501-positive non-wasp
allergic individuals who did not undergo immunotherapy at time
point A and timepoint B (4–6 weeks later). There was no
significant difference in the frequency of tetramer binding T-cells,
p=0.69, student’s paired t-test.
Found at: doi:10.1371/journal.pone.0011028.s005 (0.25 MB
TIF)
Figure S6 (A) Short term T-cell lines to rVes v 5 were generated
in 4 wasp allergic individuals at week 12 of immunotherapy in the
presence of anti-IL-10 (diagonal stripes) and after magnetic bead
depletion of CD25hi T-regs(filled). T-cell lines were then
stimulated overnight with Ves v 5 peptide pools (10 mM) and IL-
4 responses were detected by ELISpot. The results are expressed
as means and SD spots per million cells. (B) Short term lines were
also generated to FEC peptide pool with anti-IL10 and CD25
depletion and re-stimulated overnight with FEC peptide pools on
IFN-c ELISpot plates. Mean and SD spot forming units per
million cells are shown.
Found at: doi:10.1371/journal.pone.0011028.s006 (0.88 MB
TIF)
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